Company news
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) news
Protagonist Therapeutics, Inc. news releases on 6ix. Latest, Jan 6, 2025: Protagonist Therapeutics Reports Granting of Inducement Awards
Press releases — page 2
Protagonist Therapeutics Reports Granting of Inducement Awards
January 5, 2025
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
December 18, 2024
Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting
December 8, 2024
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
November 21, 2024
Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
November 20, 2024
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
November 18, 2024
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis
November 17, 2024
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 6, 2024
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
November 4, 2024
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
September 2, 2024
Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 5, 2024
Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
July 31, 2024
Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor
July 30, 2024
Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
July 21, 2024
Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control
June 13, 2024
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
May 30, 2024
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
May 13, 2024
Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
May 6, 2024
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 6, 2024
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
March 25, 2024
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
March 17, 2024
Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
March 10, 2024
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
March 5, 2024
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 26, 2024
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
February 20, 2024
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
February 6, 2024
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
January 30, 2024
Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024
January 28, 2024
Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 2, 2024
Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis
December 12, 2023
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals
December 11, 2023
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib
November 26, 2023
Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM)
November 8, 2023
Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting
November 1, 2023
Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 1, 2023
Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis
October 31, 2023
Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors
October 29, 2023
Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications
October 8, 2023
Protagonist Therapeutics to Present at Upcoming Investor Conferences
September 4, 2023
Protagonist Receives $34 Million from Warrant Exercises
August 8, 2023
Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 2, 2023
Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis
July 3, 2023
Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects o...
June 8, 2023
Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress
June 5, 2023
Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
May 31, 2023
Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113
May 11, 2023
Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference
May 10, 2023
Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association
May 10, 2023
Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 3, 2023
Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
April 3, 2023